Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response (WHO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04961229
Recruitment Status : Not yet recruiting
First Posted : July 14, 2021
Last Update Posted : October 8, 2021
Sponsor:
Information provided by (Responsible Party):
dafna yahav, Rabin Medical Center

Tracking Information
First Submitted Date  ICMJE July 13, 2021
First Posted Date  ICMJE July 14, 2021
Last Update Posted Date October 8, 2021
Estimated Study Start Date  ICMJE October 2021
Estimated Primary Completion Date February 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 10, 2021)
anti-spike protein titer above 50 AU/ml 2 weeks post vaccination [ Time Frame: 2 weeks post vaccination ]
positive humoral response against SARS-CoV-2
Original Primary Outcome Measures  ICMJE
 (submitted: July 13, 2021)
positive humoral response against SARS-CoV-2 [ Time Frame: 2 weeks post vaccination ]
anti-spike protein titer above 50 AU/ml
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 10, 2021)
  • anti-spike protein titer above 50 AU/ml 3-, 6-, and 12-months post vaccination [ Time Frame: 3-, 6-, and 12-months post vaccination ]
    positive humoral response against SARS-CoV-2
  • Log transformed titer of anti-spike protein weeks and 3, 6, and 12 months post vaccination [ Time Frame: 2 weeks and 3, 6, and 12 months post vaccination ]
    Log transformed titer of anti-spike protein
  • Adverse events to booster dose using CTCAE v4.0 criteria [ Time Frame: 2 weeks post vaccine ]
    Severity of adverse events will be assessed using CTCAE v4.0 criteria
  • Acute rejection of the allograft either documented by biopsy or clinically suspected, defined as increase in creatinine by 20% from baseline, without any other plausible explanation [ Time Frame: 2 weeks, 3,6, and 12 months post vaccination ]
    either documented by biopsy or clinically suspected, defined as increase in creatinine by 20% from baseline, without any other plausible explanation
  • positive PCR test to SARS-CoV-2 during the follow up period [ Time Frame: until 12 months following vaccine ]
    positive PCR test to SARS-CoV-2 during the follow up period
  • Positive PCR tests to VZV, CMV [ Time Frame: during the follow up period ]
    Other viral reactivation during the follow up period: VZV, CMV, tested according to clinical suspicion
  • Number of hospitalizations (numerical count) [ Time Frame: until 12 months following vaccine ]
    Number of hospitalizations
Original Secondary Outcome Measures  ICMJE
 (submitted: July 13, 2021)
  • positive humoral response against SARS-CoV-2 [ Time Frame: 3-, 6-, and 12-months post vaccination ]
    anti-spike protein titer above 50 AU/ml
  • Log transformed titer of anti S protein [ Time Frame: 2 weeks and 3, 6, and 12 months post vaccination ]
  • Adverse events to booster dose [ Time Frame: 2 weeks post vaccine ]
    Severity of adverse events will be assessed using CTCAE v4.0 criteria
  • Acute rejection of the allograft [ Time Frame: 2 weeks, 3,6, and 12 months post vaccination ]
    (either documented by biopsy or clinically suspected, defined as increase in creatinine by 20% from baseline, without any other plausible explanation
  • SARS-CoV-2 infection during the follow up period [ Time Frame: until 12 months following vaccine ]
  • Other viral reactivation during the follow up period [ Time Frame: during the follow up period ]
    VZV, CMV, tested according to clinical suspicion
  • Number of hospitalizations [ Time Frame: until 12 months following vaccine ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response
Official Title  ICMJE Booster Dose of mRNA SARS-CoV-2 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response With or Without Immunosuppression Reduction - Protocol for a Randomised Controlled Trial (BECAME Study)
Brief Summary

Introduction: Inadequate antibody response to mRNA SARS-CoV-2 vaccination has been described among kidney transplant recipients. Immunosuppression level and specifically, use of antimetabolite in the maintenance immunosuppressive regimen, are associated with inadequate response. In light of the severe consequences of COVID-19 in solid organ transplant recipients, we believe it is justified to examine new vaccination strategies in these patients.

Methods and analysis: BECAME is a single center, open label, investigator-initiated randomised controlled, superiority trial, aiming to compare immunosuppression reduction combined with a third BNT162b2 vaccine dose versus third dose alone. The primary outcome will be seropositivity rate against SARS-CoV-2. A sample size of 154 patients was calculated for the seropositivity endpoint assuming 25% seropositivity in the control group and 50% in the intervention group. A sample of participant per arm will be also teste for T-cell response. We also plan to perform a prospective observational study, evaluating seropositivity among ~350 kidney transplant recipients consenting to receive a third vaccine dose, who are not eligible for the randomised controlled trial.

Ethics and dissemination: The trial is approved by local ethics committee of Rabin medical center (RMC-0192- 21). Results of this trial will be published; trial data will be available. Protocol amendments will be submitted to the local ethics committee.

Detailed Description

All recipients more than 6 months post transplantation and at least 3 weeks following second vaccine dose will be approached and invited to a first study visit.

At first visit:

  • Signed informed consent will be obtained from participants willing to participate by study investigators who usually work in the transplantation clinic.
  • Anti-spike antibody response will be assessed using SARS-CoV-2 IgG II Quant (Abbott©) assay. Participants who have a documented seronegative test in the last 6 weeks will not be tested again.

Participants will be invited for an additional visit once negative serology will be reported, within 7 days of serology collection. At this second visit all participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.

In addition, participants in the RCT will be randomised into two groups:

  1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol
  2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response).

Patients who will test seronegative will be informed by the study coordinator by phone in which study arm they will be participating and receive instructions for immunosuppression reduction both during the phone call and by written instructions provided to each patient during the first visit (see Appendix). Participants in the observational study will receive a third vaccine standard dose, without any change in immunosuppression (beyond routine care)

For all groups:

  • Antibodies titer against spike protein will be evaluated again 2 weeks and 3, 6, 12 months after the third vaccine dose
  • T-cell response will be evaluated for a subset of patients in each group (estimated 20 patients per arm) before booster dose, at 2 weeks after booster dose, and at 3 months. For T cell response quantification peripheral blood mononuclear cell (PBMC) will be stimulated for 24 hours with spike protein and secreted interferon-gamma (IFNg) will be measured by ELISA.
  • Follow-up for adverse events, rejection and SARS-CoV-2 infection will be performed at 2 weeks and at three, 6 and 12 months post third vaccination dose
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE
  • COVID-19 Acute Respiratory Distress Syndrome
  • Immunosuppression
Intervention  ICMJE Biological: The Pfizer mRNA-based BNT162b2 vaccine

participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.

In addition, participants in the RCT will be randomised into two groups:

  1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol
  2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response).
Study Arms  ICMJE
  • Experimental: Third dose of BNT162b2 vaccine with Immunosuppression reduction
    Third dose of BNT162b2 vaccine with reduction of mycophenolic acid dose
    Intervention: Biological: The Pfizer mRNA-based BNT162b2 vaccine
  • Experimental: Third dose of BNT162b2 vaccine without immunosuppression reduction
    Third dose of BNT162b2 vaccine without reduction of mycophenolic acid dose
    Intervention: Biological: The Pfizer mRNA-based BNT162b2 vaccine
  • Experimental: Third dose of BNT162b2 vaccine
    Third dose of BNT162b2 vaccine with no change in immunosuppression for patients that are excluded from the randomised trial
    Intervention: Biological: The Pfizer mRNA-based BNT162b2 vaccine
Publications * Yahav D, Rozen-Zvi B, Mashraki T, Atamna A, Ben-Zvi H, Bar-Haim E, Rahamimov R. Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study). BMJ Open. 2021 Oct 11;11(10):e055611. doi: 10.1136/bmjopen-2021-055611.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: October 5, 2021)
504
Original Estimated Enrollment  ICMJE
 (submitted: July 13, 2021)
450
Estimated Study Completion Date  ICMJE July 2022
Estimated Primary Completion Date February 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • kidney transplant recipients that received two doses of BNT162b2 vaccine at least 3 weeks prior to enrollment, and were seronegative (IgG against the spike protein of SARS-CoV-2 below 50 AU/ml) at least two weeks after the second vaccine dose

Additional inclusion criteria for the RCT:

  • Recipients treated by three anti-rejection medications including: prednisone, tacrolimus, mycophenolate mofetil or mycophenolic acid.
  • Tacrolimus trough blood levels 5-10 nGr/ml (lower or higher doses will have to be adjusted before re-considering for inclusion)

Exclusion Criteria:

  • Past infection with SARS-CoV-2
  • Pregnancy
  • Age below 18 years
  • Active infection

Additional exclusion criteria for RCT only:

- Recipients at a high risk for acute or chronic humoral rejection including:

  • Recipients with positive panel-reactive antibody (PRA) (any positive value) at any time before or after transplantation
  • Recipients that had an acute rejection in the last year
  • Recipients less than 6 months after transplantation
  • Recipients that are considered at high risk for rejection according to the primary care nephrologist
  • Recipients taking less than 3 anti-rejection medications
  • Recipients currently treated with mTOR inhibitors (everolimus, sirolimus) and/or azathioprine
  • Recipients treated with plasmapheresis in the previous 3 months
  • Recipients treated with eculizumab in the last year
  • Recipient treated with IVIG in the previous 3 months
  • Recipient treated with rituximab in the previous 6 months
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Ruth Rahaminov 97239376475 rutir@clalit.org.il
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04961229
Other Study ID Numbers  ICMJE 0192-21-RMC
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: According to request
Supporting Materials: Study Protocol
Supporting Materials: Informed Consent Form (ICF)
Time Frame: The data will become available once entered for all patients and analyzed, presumably at 1-January-2022. It will be available for one year.
Access Criteria: Researchers who would like to share the data will be requested to send the PI their protocol/reason for asking the data. After reviewing the request, if the protocol seems adequate in terms of clinical question and methodological quality, we will share anonymized data.
Responsible Party dafna yahav, Rabin Medical Center
Study Sponsor  ICMJE dafna yahav
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ruth Rahaminov Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel
PRS Account Rabin Medical Center
Verification Date October 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP